Home › Trials › NCT06504446

Assessing a new treatment for chronic cough in adults

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough

Phase 2 Interventional Nocion Therapeutics · NCT06504446

This study is testing a new inhalation treatment for adults with a stubborn chronic cough to see if it helps them feel better compared to a placebo.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment455 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorNocion Therapeutics Industry-sponsored
Locations107 sites (Foley, Alabama and 106 other locations)
Trial IDNCT06504446 on ClinicalTrials.gov

What this trial studies

This phase 2b clinical trial evaluates the efficacy, safety, and tolerability of NOC-110, an inhalation powder, in adults suffering from refractory or unexplained chronic cough. Approximately 325 participants will be enrolled, with an anticipated screening of up to 600 individuals. The study will be randomized, double-blind, and placebo-controlled, lasting about 13 weeks. Participants will receive either the active treatment or a placebo once daily.

Who should consider this trial

Good fit: Ideal candidates are adults with a chronic cough lasting 12 months or more that is refractory or unexplained.

Not a fit: Patients with chronic obstructive pulmonary disease, bronchiectasis, or other significant pulmonary diseases will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate chronic cough symptoms for patients who have not responded to other therapies.

How similar studies have performed: While this approach is novel, similar studies targeting chronic cough have shown varying degrees of success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Refractory or unexplained chronic cough for ≥ 12 months.
* Women of childbearing potential agree to follow the protocol specified contraceptive - guidance during the study.
* Males who are not vasectomized must agree to use the contraceptive methods defined in the protocol.
* Able to provide Informed Consent.

Exclusion Criteria:

* Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds.
* Participants who are currently participating in another drug or device clinical study
* Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening.
* Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease.
* Respiratory tract infection within 4 weeks of Screening or during screening period.
* Any female who is pregnant or lactating or wishing to become pregnant.
* Donation of \> 1 Unit (450 milliliter or more) of blood within 60 days prior to the first dosing.
* Alcohol or drug use disorder within the past 2 years.
* Current smoker/vaper or individuals who have given up smoking within the past 6 months of screening, and/or those with \>20 pack-year smoking history.
* Current opiate/opioid use or medical history of opiate/opioid use disorder.
* History of concurrent malignancy or recurrence of malignancy in the last 2 years.
* Body Mass Index of ≥40 kg/m2.
* Positive results for human immunodeficiency virus, hepatitis B, or hepatitis C virus.
* Unable to refrain from the use of medications and treatments that can impact cough during the study.
* Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).

Where this trial is running

Foley, Alabama and 106 other locations

+57 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Refractory or Unexplained Chronic Cough
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.